Kestutis Rucinskas1, Vilius Janusauskas2, Diana Zakarkaite1, Sigita Aidietiene1, Robertas Samalavicius3, Giovani Speziali4, Audrius Aidietis1. 1. Department of Cardiovascular Medicine, Vilnius University, Vilnius, Lithuania. 2. Department of Cardiovascular Medicine, Vilnius University, Vilnius, Lithuania. Electronic address: janvilius@yahoo.com. 3. Centre of Anaesthesia, Intensive Care, and Pain Management, Department of Intensive Care, Vilnius University, Vilnius, Lithuania. 4. Department of Cardiothoracic Surgery, University of Pittsburgh Physicians, Pittsburgh, Pa.
Abstract
OBJECTIVES: This study evaluated the safety and efficiency of the NeoChord DS1000 system (NeoChord, Inc, Minneapolis, Minn), a device designed to deliver artificial chordae tendineae (neochords) in a beating heart with minimally invasive techniques through left anterolateral minithoracotomy. METHODS: Thirteen patients with severe mitral regurgitation and isolated posterior mitral valve leaflet prolapsed underwent operation with the NeoChord DS1000 system. Mitral valve dimensions were anteroposterior 34 mm (29-45 mm) and mediolateral 40 mm (29-58 mm). All patients had an ejection fraction greater than 55%. With a beating heart, through a left anterolateral thoracotomy, under transesophageal echocardiographic guidance, the NeoChord DS1000 was introduced into the left ventricle 2 to 4 cm posterolateral from the apex. The prolapsed leaflet was grasped with the device, and expanded polytetrafluoroethylene suture deployed and attached to the posterior leaflet. Six patients received 2 sutures, 4 received 3 sutures, and 2 received 4 sutures. All patients reached 6 months' follow-up and underwent transthoracic echocardiography to evaluate mitral regurgitation. RESULTS: Median operative duration was 113 minutes (80-150 minutes). Less than second-degree mitral regurgitation in 6 months was achieved in 11 patients (85%). One patient (8%) had recurrent mitral regurgitation in 1 month, and another had conversion to conventional mitral valve repair because of leaflet damage with the device. There were no further serious procedure-related complications. CONCLUSIONS: Beating-heart transapical neochord implantation was feasible, could be performed safely, and resulted in a relatively short procedure time. Larger studies and longer follow-up are needed to validate these promising results.
OBJECTIVES: This study evaluated the safety and efficiency of the NeoChord DS1000 system (NeoChord, Inc, Minneapolis, Minn), a device designed to deliver artificial chordae tendineae (neochords) in a beating heart with minimally invasive techniques through left anterolateral minithoracotomy. METHODS: Thirteen patients with severe mitral regurgitation and isolated posterior mitral valve leaflet prolapsed underwent operation with the NeoChord DS1000 system. Mitral valve dimensions were anteroposterior 34 mm (29-45 mm) and mediolateral 40 mm (29-58 mm). All patients had an ejection fraction greater than 55%. With a beating heart, through a left anterolateral thoracotomy, under transesophageal echocardiographic guidance, the NeoChord DS1000 was introduced into the left ventricle 2 to 4 cm posterolateral from the apex. The prolapsed leaflet was grasped with the device, and expanded polytetrafluoroethylene suture deployed and attached to the posterior leaflet. Six patients received 2 sutures, 4 received 3 sutures, and 2 received 4 sutures. All patients reached 6 months' follow-up and underwent transthoracic echocardiography to evaluate mitral regurgitation. RESULTS: Median operative duration was 113 minutes (80-150 minutes). Less than second-degree mitral regurgitation in 6 months was achieved in 11 patients (85%). One patient (8%) had recurrent mitral regurgitation in 1 month, and another had conversion to conventional mitral valve repair because of leaflet damage with the device. There were no further serious procedure-related complications. CONCLUSIONS: Beating-heart transapical neochord implantation was feasible, could be performed safely, and resulted in a relatively short procedure time. Larger studies and longer follow-up are needed to validate these promising results.
Authors: G Casadesus; C S Atwood; X Zhu; A W Hartzler; K M Webber; G Perry; R L Bowen; M A Smith Journal: Cell Mol Life Sci Date: 2005-02 Impact factor: 9.261
Authors: Katarzyna Kurnicka; Krzysztof Wróbel; Olga Zdończyk; Maksymilian Bielecki; Zbigniew Juraszyński; Andrzej Biederman; Piotr Pruszczyk Journal: Postepy Kardiol Interwencyjnej Date: 2019-01-21 Impact factor: 1.426
Authors: Krzysztof Wróbel; Katarzyna Kurnicka; Marcin Zygier; Dariusz Zielinski; Wojciech Dyk; Ryszard Wojdyga; Zbigniew Juraszynski; Piotr Pruszczyk; Andrzej Biederman Journal: Wideochir Inne Tech Maloinwazyjne Date: 2019-02-05 Impact factor: 1.195